Skip to content

Search

New cultural safety initiative guides best practice for clinical research

Perth investigators involved in a major global trial have launched an innovative Cultural Information Hub to maximise cultural safety for Aboriginal and/or Torres Strait Islander patients participating in research.

Simple SMS ‘nudge’ a powerful prompt for timely vaccination

10,000 families participating in research by The Kids Research Institute Australia have demonstrated the effectiveness of a simple text message for increasing the number of children receiving their vaccinations on time.

National-first RSV immunisation program welcomed by The Kids Research Institute Australia

The Kids Research Institute welcomes WA's $11M RSV immunisation program, offering free Nirsevimab to infants, aiming to reduce winter hospitalisations.

COVID-19 risks explained for babies, children and pregnant women

Many parents may be feeling anxious and confused about what COVID-19 means for pregnant women, babies and children.

Invasive fungal disease in children with solid tumors: An Australian multicenter 10-year review

Invasive fungal disease (IFD) occurs less frequently during treatment for solid compared to hematological malignancies in children, and risk groups are poorly defined. Retrospective national multicenter cohort data (2004-2013) were analyzed to document prevalence, clinical characteristics, and microbiology of IFD.

Impact of Parent-Reported Antibiotic Allergies on Pediatric Antimicrobial Stewardship Programs

Antimicrobial stewardship (AMS) is crucial for optimizing antimicrobial use and restraining emergence of antimicrobial resistance. The overall increase in reported antibiotic allergies in children can pose a significant barrier to AMS, but its impact on clinical AMS care in children has not been addressed.

Assessing the Impact of Pneumococcal Conjugate Vaccine Immunization Schedule Change From 3+0 to 2+1 in Australian Children: A Retrospective Observational Study

In mid-2018, the Australian childhood 13-valent pneumococcal conjugate vaccine schedule changed from 3+0 to 2+1, moving the third dose to 12 months of age, to address increasing breakthrough cases of invasive pneumococcal disease (IPD), predominantly in children aged >12 months. This study assessed the impact of this change using national IPD surveillance data.

New pneumococcal vaccine closes in on approval

Pneumococcal – a bacterial infection that can cause pneumonia and meningitis – is responsible for 1000s of hospital admissions in Australia each year, many of them children.

The measurement properties of tests and tools used in cystic fibrosis studies: a systematic review

There is no consensus on how best to measure responses to interventions among children and adults with cystic fibrosis (CF). We have systematically reviewed and summarised the characteristics and measurement properties of tests and tools that have been used to capture outcomes in studies among people with CF, including their reliability, validity and responsiveness. This review is intended to guide researchers when selecting tests or tools for measuring treatment effects in CF trials. A consensus set of these tests and tools could improve consistency in how outcomes are captured and thereby facilitate comparisons and synthesis of evidence across studies.

Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens

Recent data indicate excessive weight gain in treatment-naive adults with HIV commenced on antiretroviral therapy (ART) regimens containing tenofovir alafenamide (TAF) or the integrase strand transfer inhibitors (INSTIs) dolutegravir (DTG) and bictegravir.